VDR and myeloid leukemia: Amantadine, an FDA-approved antiviral and anti-Parkinson agent, is associated with a monocyte-macrophage-like differentiation of HL60, U937, and Kasumi-1 myeloid leukemia cell lines by inducing vitamin D receptor (VDR) expression (Manzotti et al., 2015).